Surgery Partners: An Overview of its Recent Results and Analyst Coverage
The healthcare industry is one of the most important industries in the world. This is because everyone, at some point in their lives, will require medical attention. As such, investing in healthcare companies has become a popular strategy for many investors. One company that has caught the attention of equity research analysts is Surgery Partners.
Last Thursday, analysts at StockNews.com assumed coverage on shares of Surgery Partners (NASDAQ:SGRY). In a research note issued by the firm, they set a “hold” rating on the stock. This signals a neutral stance from the analysts.
Investors who are considering investing in Surgery Partners can review the company’s recent financial results to make an informed decision. The last earnings report was released on May 1st, and it showed that the company had earnings per share (EPS) of $0.05 for that quarter. This beat analysts’ consensus estimates of ($0.04) by $0.09, which bodes well for investors.
One key metric in evaluating a company’s profitability is return on equity (ROE). For Surgery Partners, it had a positive ROE of 0.59% during the last quarter. However, its net margin was negative at 3.51%. This means that while the company generated revenue of $666.20 million for that quarter – higher than analyst estimates of $644.16 million – it had some challenges managing its costs.
Surgery Partners has three business segments: Surgical Facility Services, Ancillary Services, and Optical Services. These segments provide solutions for surgical and related ancillary care to support patients and physicians.
In summary, Surgery Partners has recently received analyst coverage with a “hold” rating from StockNews.com, and it posted quarterly financial results with better-than-expected EPS but negative net margin performance. Investors who are interested in this healthcare services holding company may want to monitor its future financial performance and industry trends to make informed investment decisions.
[bs_forecast_slider ticker=”SGRY”]
Surgery Partners Inc: A Growing Healthcare Services Company With Bullish Attitudes From Investors
Surgery Partners Inc, a healthcare services company, provides crucial surgical and ancillary care solutions to patients and physicians. In recent times the company has been under review by several research analysts who have swarmed in on the stock to investigate its standing in the market. Ratings have ranged from moderate buy to overweight signal with price objectives variably falling between $43.00 and $56.00 for this worth billion dollar firm that specializes in surgical facilities, ancillary services and optical services.
The firm’s shares opened at $36.68 on Thursday, April 22 with a market capitalization of $4.64 billion. The stock remained steady within an impressive 12-month high range of $46.22 and low of $20.46 ranking it as a preferred choice for investors seeking stability in the sector.
Recent insider dealings involving CEO Jason Eric Evans and Bradley R Owens have slightly affected the security shares as these transactions become public knowledge, however overall balance still remains steady given the numbers of institutional investors investing deeply into this company’s future potential.
Big players such as Assenagon Asset Management S.A., UBS Group AG, Durable Capital Partners LP, Sivik Global Healthcare LLC and MetLife Investment Management LLC saw value in investing into Surgery Partners Inc including significant sit-ins before completing financial reports whose results went live yielding a clean bill of health for Surgery Partners’ fiscal year end figures wrapped up by December 2016.
Overall consensus rates show that Surgery Partners Inc is winning both investors’ confidence and trust with continued growth being reported by independent industry figures while management continues to push out innovative solutions aimed at improving older traditional forms of surgical procedures to align with modern healthcare standards by meeting patient needs faster while speedily assisting health practitioners attain quicker accurate results all around.
Taking everything reviewed in stride it can be concluded that Surgery Partners is heading towards carving out its name as an innovator considerably disrupting how healthcare treatment options will be administered both now and in the future as investors continue showing bullish attitudes towards making even more investments into an already prosperous public company, worthy of attention from new entrants looking for a solid investment option.
